UC-MSCs for Type 2 Diabetes Stem Cell Therapy Aspects
Type 2 Diabetes is a chronic metabolic disorder associated with insulin resistance, progressive an progressively variable beta-cell dysfunction, low-grade systemic and local inflammation, and poor glycemic control. The body is often still able to make insulin but the cells are resistant to it in many patients. The pancreas will eventually not be able to provide sufficient insulin, causing increased blood sugar levels and reduced compensation capacity resulting in higher long-term metabolic risk, HbA1c elevation etc.
As Type 2 Diabetes is characterized by both metabolic imbalance and inflammatory stress during the development of diabetic complications, stem cell therapy with unbilical cord derived mesenchymal stem cells (UC-MSC) appears to be a promising regenerative medicine approach. An alternative cell type for research is umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs), which have been shown to release bioactive signals with potential therapeutic power by promoting immune balance, relieving uncontrolled inflammation, improving the pancreatic microenvironment and supporting metabolic function.
Stem cell therapy for the treatment of Type 2 Diabetes as a cure. It is not meant to be a substitute for basic diabetes management, medication, insulin when appropriate, nutrition planning and exercise (in the proper amount), blood glucose monitoring or endocrinology follow-up. Otherwise, UC-MSCs might be viewed more as an adjunct with regenerative research potential in select patients following medical evaluation.
What Are UC-MSCs?
UC-MSCs are mesenchymal stem/stromal cells sourced from the umbilical cord tissue of healthy consenting mothers post childbirth. They are the most studied as they can secrete growth factors, cytokines, extracellular microvesicles cell signaling molecules.
In humans with Type 2 Diabetes, however, UC-MSCs are acting on a broader scale, and are not replacing pancreatic cells. Biosensors of their value is more as disease modifiers for how they might be able to mediate internal homeostasis bought through paracrine mechanism, modulation of immune response, anti-inflammatory effects and support directional beta-cell function.
Advantages of Stem Cell Therapy for Type 2 Diabetes
Supporting Insulin Resistance
Insulin resistance is one of the main problems in Type 2 Diabetes. This causes the cells in the body to become resistant to insulin, and hence, making the pancreas overwork just to keep blood sugar under control.
It is believed that UC-MSCs support insulin sensitivities via both a decrease in inflammatory stress and an improvement in the tissue milieu for glucose handling. A body with a more balanced control of inflammation is in a potentially ideal environment for healthy metabolism.
Helping Improve Glycemic Control
The most used markers to evaluate good glycemic control are fasting blood glucose, postprandial glucose levels and HbA1c, along with the day glycemia stability.
The administration of UC-MSC may be effective for the selected patients in order to better improving their glucoregulatory environment. The aim is to make it easier to maintain metabolic harmony, decrease inflammatory burden, and allow the body to respond more effectively to any pre-existing diabetes management.
Supporting Beta-Cell Function
Insulin-producing beta cells in the pancreas Beta-cell function is frequently lost in Type 2 Diabetes owing to metabolic stress, inflammation and the demand of insulin over a long period of time.
UC-MSCs potentially play a beneficial role in the beta-cell environment via anti-inflammatory and tissue-supportive signaling. This could contribute in creating a better pancreatic microenvironment and preserve the function of the existent beta-cell mass.
Figure 1: Potential Advantages of UC-MSC Therapy for Type 2 Diabetes
Reducing Chronic Low-Grade Inflammation
As such, Type 2 Diabetes is not just a blood sugar issue. It is also associated with chronic low-grade inflammation that can impact insulin sensitivity, blood vessels, adipose tissue, liver metabolism and pancreatic function.
UC-MSCs have been investigated for their anti-inflammatory and immunomodulatory properties. UC-MSCs may therefore promote a more favorable milieu for metabolic homeostasis through the regulation of inflammatory pathways, especially in patients with high inflammatory burden or prolonged insulin resistance.
Supporting Vascular and Tissue Health
Type 2 diabetes long-term complication may include: diseases of the blood vessels or nerves, kidney failure (end-stage renal), blindness (also in young people!), some skin and wound care. UC-MSCs might release different growth factors and extracellular vesicles to promote signaling related to tissue-repair events at the site of injury and also help maintain vascular health.
Prospective Synergistic Roles of UC-MSCs in Type 2 Diabetes
Stem cell therapy using UC-MSCs could contribute to support during:
Insulin resistance balance
Inflammatory control
Beta-cell function signaling
Metabolic stability
Tissue-repair support
Vascular and circulation support
The response likely differs based on the duration of diabetes, baseline HbA1c, insulin sensitivity or resistance (e.g., measured via C-peptide or other means), BMI and % changes in fat mass/FFM, level of inflammation [reviewed by Lu et al.], use of glucose-lowering medications at the time of study and various lifestyle factors (e.g., dietary food choices, smoking habits etc.) that may influence responsiveness to a given intervention among patients even with seemingly comparable health conditions.
The following should provide some insight into who might use UC-MSC support that may have Type 2 diabetes?
Support with UC-MSCs might be appropriate for certain patients suffering from Type 2 Diabetes only after comprehensive clinical assessment. Important factors may include:
HbA1c and glucose pattern
Fasting glucose and post-meal glucose
C-peptide level
Insulin resistance status
Current medication or insulin requirement
Kidney and liver function
Inflammatory markers
BMI and metabolic health
Duration of diabetes
Existing complications
Overall health condition
Referral for regenerative support is advised in patients with active infection, unstable medical conditions or severe organ impairment, inadequately controlled blood sugar levels or other high-risk conditions that may warrant further medical review prior to consideration of regenerative therapy.
Important Medical Note
Conclusions: Stem cell therapy using UC-MSCs could not be proposed as a solution asserting a cured disease of Type 2 Diabetes. Do not use a diabetes medication, insulin, glucose monitoring, dieting exercise or care in endocrinology.
This should be seen as a supportive, exploratory regenerative therapy benefiting selected patients who can achieve improvements in local biology related to inflammatory-, metabolic- and tissue repair-related physiology.
Conclusion
Stem cell therapy employing UC-MSCs for Type 2 Diabetes is a novel adjuvant therapy option directed at resolving insulin resistance and inflammation, enhancing beta-cell function signaling, maintaining metabolic balance and providing tissue-repair-defense.
Through paracrine signaling, immune modulation, and anti-inflammatory effects, UC-MSCs may be able to ameliorate the internal environment. In selected patients, this may provide another supportive measure in addition to routine care of Type 2 Diabetes.
Regardless, management should always be stream-lined through clinical care (Both active and passive patient selection with appropriate expectations in mind), in conjunction to glycemic monitoring and endocrine follow-up care.